GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Cash Flow from Investing

HighTide Therapeutics (HKSE:02511) Cash Flow from Investing : HK$346.36 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the six months ended in Dec. 2023, HighTide Therapeutics spent HK$0.80 Mil on purchasing property, plant, equipment. It gained HK$0.00 Mil from selling property, plant, and equipment. It spent HK$0.00 Mil on purchasing business. It gained HK$0.00 Mil from selling business. It spent HK$162.96 Mil on purchasing investments. It gained HK$215.15 Mil from selling investments. It paid HK$0.00Mil for net Intangibles purchase and sale. And it paid HK$1.48 Mil for other investing activities. In all, HighTide Therapeutics gained HK$49.90 Mil on investment activities in financial market and operating subsidiaries for the six months ended in Dec. 2023.


HighTide Therapeutics Cash Flow from Investing Historical Data

The historical data trend for HighTide Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Cash Flow from Investing Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Cash Flow from Investing
1.94 -464.18 346.35

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Investing - 3.22 -467.25 296.45 49.90

HighTide Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

HighTide Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

HighTide Therapeutics's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$346.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HighTide Therapeutics  (HKSE:02511) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

HighTide Therapeutics's purchase of property, plant, equipment for the six months ended in Dec. 2023 was HK$-0.80 Mil. It means HighTide Therapeutics spent HK$0.80 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

HighTide Therapeutics's sale of property, plant, equipment for the six months ended in Dec. 2023 was HK$0.00 Mil. It means HighTide Therapeutics gained HK$0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

HighTide Therapeutics's purchase of business for the six months ended in Dec. 2023 was HK$0.00 Mil. It means HighTide Therapeutics spent HK$0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

HighTide Therapeutics's sale of business for the six months ended in Dec. 2023 was HK$0.00 Mil. It means HighTide Therapeutics gained HK$0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

HighTide Therapeutics's purchase of investment for the six months ended in Dec. 2023 was HK$-162.96 Mil. It means HighTide Therapeutics spent {stock_data.stock.currency_symbol}}162.96 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

HighTide Therapeutics's sale of investment for the six months ended in Dec. 2023 was HK$215.15 Mil. It means HighTide Therapeutics gained HK$215.15 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

HighTide Therapeutics's net Intangibles purchase and sale for the six months ended in Dec. 2023 was HK$0.00 Mil. It means HighTide Therapeutics paid HK$0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

HighTide Therapeutics's cash from discontinued investing activities for the six months ended in Dec. 2023 was 0.00 Mil. It means HighTide Therapeutics paid HK$0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

HighTide Therapeutics's cash from other investing activities for the six months ended in Dec. 2023 was HK$-1.48 Mil. It means HighTide Therapeutics paid HK$1.48 Mil for other investing activities.


HighTide Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


HighTide Therapeutics (HKSE:02511) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Executives
Ma Lixiong 2101 Beneficial owner
Liu Liping 2101 Beneficial owner
Li Li 2201 Interest of corporation controlled by you
The Core Trust Company Limited
Shan Miao 2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc. 2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p 2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited 2101 Beneficial owner
Hepalink (hong Kong) Limited 2201 Interest of corporation controlled by you
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 2501 Other
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited 2101 Beneficial owner
Lai Hoi Man 2201 Interest of corporation controlled by you
Hongtu Capital Limited 2101 Beneficial owner

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines